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Breast cancer is the most common type of cancer and the second most common cause of cancer death in the female population.1 Despite the fact 
that over 90% of women with breast cancer will be diag-
nosed at a loco-regional stage, almost half of them will 
relapse and eventually die, as metastatic breast cancer is 
currently an incurable disease.1 Chemotherapy has tra-
ditionally been the mainstay of treatment of metastatic 
disease. 
The advent of targeted therapies has revolutionized 
the treatment of many types of cancer, including breast 
cancer. Targeted therapies are specifically designed to 
target certain molecules that are expressed mainly on 
cancer cells and to a lesser degree on normal tissues. 
These targets may be located on the cell membrane,2,3 
inside or outside the cancer cell and when mutated or 
overexpressed, their activation may lead to increased 
proliferation, angiogenesis and inhibition of apoptosis 
thus giving the malignant phenotype.4
The concept of targeted therapy is not new in oncol-
ogy. The first targeted therapy used in breast cancer was 
tamoxifen. Tamoxifen targets the intracellular steroidal 
estrogen receptor (ER). Women with breast cancer 
whose tumors express ERs benefit by tamoxifen use, 
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the advent of targeted therapies has revolutionized the treatment of certain types of cancer. identification 
of molecular targets on cancer cells has led to the design of novel drugs, which either used as single agents 
or in combination with chemotherapy, has prolonged survival in metastatic disease, or contributed to cu-
rative treatment in the adjuvant setting. a literature review was conducted to identify and present current 
knowledge on the molecular function of the hEr2 receptor, its role in the pathogenesis of breast cancer 
and anti-hEr2 targeted drugs in use or under development. many molecular targets have been identified 
in breast cancer, with the hEr family of receptors being the ones most extensively studied. trastuzumab 
and lapatinib target the hEr2 receptor and are approved drugs for the treatment of metastatic breast can-
cer. several other targeted agents, including t-Dm1, pertuzumab, neratinib, afatinib and ertumaxomab, 
are currently being tested in vivo as well as in clinical studies. the use of targeted therapies in metastatic 
breast cancer has improved prognosis, increased survival and dramatically changed the way we treat 
breast cancer patients today.
when given as adjuvant treatment or in the metastatic 
disease setting.5 Other selective estrogen receptor mod-
ulators, as well as selective estrogen receptor down-reg-
ulators (eg, fulvestrant), aromatase inhibitors (AIs; eg, 
anastrazole, letrozole, exemestane) and gonadotrophin-
releasing hormone analogs (eg, goserelin) can all be 
considered targeted therapies. Currently, when we dis-
cuss targeted therapies, we are referring to drugs such 
as tyrosine kinase inhibitors (TKIs) and monoclonal 
antibodies (moAbs) which interfere with and block the 
function of their specific targets, thus inhibiting pro-
liferation, the metastatic potential of cancer cells and 
angiogenesis while promoting cell death, or apoptosis. 
Molecular subtypes of breast cancer and potential 
targets
Traditionally, prognostic predictions and recommenda-
tions for adjuvant therapy for patients with early stage 
breast cancer were based on pathologic determinations 
of tumor size, lymph node status, ER and human epi-
dermal growth factor receptor 2 (HER2) status.6 Today 
however, these are considered only crude indicators. A 
new molecular classification, based on gene expression 
microarrays, identified five different molecular subtypes 
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of breast cancer and proved the remarkable heteroge-
neity of breast cancer.7 These subtypes are luminal A, 
luminal B, basal-like, HER2 positive and normal-like. 
The luminal A subtype has the best prognosis, basal 
like and HER2 positive the worst and luminal B has 
an intermediate prognosis. Luminal A is characterized 
by high expression of ERs and/or progesterone recep-
tors (PRs), no expression for HER2 and low expres-
sion of other proliferation markers. Luminal B is ER 
and/or PR positive, but also HER2 positive and with 
higher expression of proliferation markers. The HER2-
positive subtype is negative for ER and PR expression. 
Basal-like is usually negative for ER, PR and HER2, 
but positive for CK5/6 and/or epidermal growth factor 
receptor (EGFR).8 However, it has now become clear 
that not all basal-like tumours demonstrate a triple 
(ER, PR, HER2) negative phenotype and conversely, 
not all triple negative tumors express a basal-like gene 
expression profiling.9 Normal-like are unclassified 
breast carcinomas which are negative for all markers 
(Table 1).10 
Hereditary breast cancer arising in carriers of muta-
tions in the BRCA1 and BRCA2 genes11 differs from 
sporadic breast cancer and from non-BRCA1/2 fa-
milial breast carcinomas. The majority of cancers that 
carry a BRCA1 germline mutation have a triple negative 
phenotype and are shown to express basal cytokeratins 
and EGFR by immunohistochemistry (IHC). These 
similarities, along with some other common cytoge-
netic abnormalities (p53 mutations, loss of 5q and loss 
of X chromosome inactivation) suggest that even in the 
absence of a germline BRCA1 mutation, the BRCA1 
pathway function is compromised in basal-like tu-
mors.12 The basal-like phenotype is only occasionally 
found in BRCA2 carcinomas, which tend to be ER and 
PR positive. Sporadic basal-like tumors usually, but not 
always, harbor BRCA1 mutations.13
The surface of cancer cells express hundreds of dif-
ferent types of receptors. Each receptor has its own 
specific ligands which function mostly as growth fac-
tors. One ligand can activate more than one receptor 
while a receptor can be activated by more than one li-
gand.4 Usually these receptors form dimers (eg, HER1 
and HER2) before their activation. There are also in-
tracellular receptors (eg, ER). The binding of a ligand to 
its receptor, which acts as tyrosine kinase (phosphoryla-
tion of a tyrosine residue) activates an intracellular sig-
nal transduction cascade to the nucleus. Each receptor 
has its own signal transduction pathway but often some 
steps are common for many pathways.14 Overexpression 
of growth factors, mutation or overexpression of re-
ceptors or their corresponding signal transducers are 
common findings in cancer and they lead to increased 
proliferation, metastasis, angiogenesis and inhibition of 
apoptosis.4 Interruption of any of the steps of a given 
pathway could potentially lead to cell death. Therefore, 
drugs are currently being designed to target these mol-
ecules; strategies to improve their use, as combination 
with other drugs, potentiation of their action and over-
coming resistance, are subjects of intense study. We pres-
ent current knowledge on HER2 receptor and the main 
anti-HER2 targeted drugs in use or under development 
(Figure 1, Table 2).
targeting the hER2 receptor—trastuzumab 
Human epidermal growth factor receptors (HER) 1, 
2, 3 and 4 (EGFR/ErbB1, ErbB2, ErbB3, ErbB4), are 
a family of receptors expressed in normal tissues and in 
many types of cancer.15 All members of the HER fam-
ily consist of an extracellular ligand binding site, a trans-
membrane domain, and an intracellular tyrosine kinase 
domain. Dimerization is required to activate tyrosine 
kinase phosphorylation.15 Dimerization can be either 
homodimerization, between two molecules of the same 
type, or heterodimerization between two molecules of dif-
ferent types. The phosphorylated HER dimers activate 
downstream cell proliferation (mitogen-activated protein 
kinase), cell survival (phosphoinositide 3-kinase), and 
signal transducer and activator of transcription path-
ways.16 HER1 (EGFR) and HER2 are the most signifi-
cant and better studied so far. HER2 is overexpressed 
and amplified in 20% to 30% of human breast cancers17 
which follow a more aggressive course of disease and cor-
relate with poor prognosis, including high risk of recur-
rence, metastasis and reduced overall survival.18 HER2 
overexpression is also a predictive factor of response 
Table 1. Classification of breast cancer based on hormone and surface receptor   expression.
Luminal A Luminal B HER2 (+) Basal-like/BRCA+ Normal-like
er(+)
pr(+)
Her2(-)
er(+)
pr(+)
Her2(+)
er(-)
pr(-)
Her2(+)
er(-)
pr(-)
Her2(-)
CK5/6 (+)
egFr (Her1) (+)
all markers
negative
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to chemotherapy and hormonal treatment. Therefore, 
HER2 seems to play a significant role in the pathogenesis 
of breast cancer. Several mechanisms have been proposed 
to associate HER2 overexpression/amplification with 
carcinogenesis including:
·  Formation of HER2 containing heterodimers which 
lead to enhanced downstream signaling19
·  Increased recycling of EGFR to the cell surface that 
also leads to enhanced downstream signaling20
·  Formation of HER2 homodimers, some truncated 
and constitutively active
·  Activation or suppression of signal transduction 
pathways, important in tumor development and 
growth.21
Assessment of HER2 status of patients is currently 
being performed by using either immunohistochemistry 
to evaluate protein overexpression, or fluorescence in 
situ hybridization (FISH), chromogenic in situ hybrid-
ization (CISH) and silver-enhanced in situ hybridiza-
tion (SISH) to evaluate gene amplification.22,23 HER2 
extracellular domain (ECD) levels can be found elevated 
in patients with HER2 negative (by IHC or FISH/
CISH/SISH) breast cancer and recent reports suggest 
that these patients do benefit from HER2 targeting 
therapy.24,25 
Trastuzumab is a humanized IgG1 monoclonal an-
tibody against the extracellular domain of the HER2 
receptor.26 Proposed potential mechanisms to explain its 
antitumor effects include: 
·  Inhibition of proliferation and angiogenesis medi-
ated through HER2 signaling.27
·  Immune response against tumor cells via antibody-
dependent cell-mediated cytotoxicity (ADCC).28
·  Prevention of homodimerization of truncated 
HER2 receptors through inhibition of cleavage of 
the HER2 ECD by metalloproteinases.29 
·  Acceleration of the internalization and degradation 
of HER2 from the cell membrane.30 
Trastuzumab as first line treatment
Initial studies evaluated trastuzumab as single agent and 
found an overall response rate (ORR) of 11% to 15% 
and 26% in pretreated31 and untreated32 patients respec-
tively. The first randomized phase III trial to study the 
combination of trastuzumab with chemotherapy in the 
first line setting enrolled 469 women with HER2 posi-
tive (IHC: 2+,3+) metastatic breast cancer.33 Patients 
received either an anthracycline (doxorubicin or epiru-
bicin) with cyclophosphamide (if they had not received 
anthracyclines as adjuvant treatment) or paclitaxel with 
or without trastuzumab. Patients in the chemotherapy 
only arm could cross over to receive trastuzumab at dis-
Table 2. Overview of therapeutic strategies for Her2 positive metastatic breast cancer.
Agent Type Mechanism of action
Trastuzumab Monoclonal antibody extracellular domain, effective against Her2 homodimers
Lapatinib reversible TKi
Selective inhibitor of egFr/
Her1 and Her2 intracellular 
tyrosine kinases
T-dM1 antibody-drug conjugate
Trastuzumab conjugated to an 
anti-microtubule
agent (maytansine). 
Maytansine is a potent anti-
microtubule agent
pertuzumab Monoclonal antibody
extracellular domain different 
than trastuzumab, inhibits 
hetero-dimerization
neratinib irreversible TKi pan-Her TKi
afatinib irreversible TKi pan-Her TKi
ertumaxomab Trifunctional, bispecific antibody
Targets both Her2
receptor (extracellular domain 
different epitope), Cd3 antigen 
on T cells and activates Fc-
gamma receptors
TKi: Tyrosine kinase inhibitor.
Figure 1. The Her family of receptors and their corresponding targeted drugs.
ease progression. The study met its primary endpoint—
time-to-progression (TTP) was prolonged from 4.6 to 
7.4 months (P<.001) for patients who received trastu-
zumab. ORR (50% vs. 32%, P<.001), median duration 
of response (9.1 vs. 6.1, P<.001) and median overall 
survival (OS) (25.1 vs. 20.3 months, P<.046) were all 
significantly improved in favor of the trastuzumab arm. 
This study led to the approval of trastuzumab in com-
bination with chemotherapy for the treatment of meta-
static breast cancer in the first line. 
Several other chemotherapy agents were tested in 
phase II studies with trastuzumab and the combination 
was found to be active with response rates ranging from 
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20% to 68%. Vinorelbine,34 capecitabine,35 docetaxel,36 
paclitaxel,37 platinum agents38 and gemcitabine39 are 
all now considered good partners of trastuzumab. 
Increased rates of cardiac toxicity when trastuzumab is 
combined with anthracyclines inhibits their concurrent 
use,40 although the combination seems very active; re-
cent reports from patients who received both drugs as 
neoadjuvant treatment suggest that cardiotoxicity is not 
a major issue.41 The trend at present, however, is not to 
use these two drugs concurrently.
Trastuzumab at disease progression
How should patients be treated when they progress on 
trastuzumab? The experience derived from the use of 
chemotherapy denotes that when disease progresses 
while on treatment with a certain chemotherapeutic 
agent, that agent should be discontinued and another 
one should be used, but with trastuzumab, disease pro-
gression does not necessarily reflect inactivity of the 
drug. Possibly, the HER2 signaling pathway is triggered 
by another pathway because of intracellular crosstalk, 
but trastuzumab acts by other mechanisms (eg, ADCC 
cytotoxicity) which are probably still active and could 
act synergistically with another chemotherapy drug.42 
A similar paradigm is the case of prostate cancer where 
luteinizing hormone-releasing hormone (LHRH) ana-
logs are used even when the disease becomes hormone 
resistant. 
A phase III study confirmed the above assumption. 
Patients with HER2-positive metastatic breast cancer 
who had progressed on trastuzumab-containing ther-
apy were treated either with capecitabine with trastu-
zumab or capecitabine alone. Of the planned 482 pa-
tients, only 156 were enrolled as the study was halted 
by an independent data monitoring committee. At a 
median follow up of 15.6 months, progression-free sur-
vival (PFS) was improved in favor of the combination 
arm (8.2 vs. 5.6 months) (P=.03).43 
Are there any predictors for activity of second line 
trastuzumab-based therapy? The only study to address 
this question is a retrospective study by Bartsch and 
colleagues who reviewed the data of 97 patients treated 
with more than one line of a trastuzumab-containing 
regimen.44 In a multivariate analysis, no clinical or his-
topathological features could reliably predict the activ-
ity of second-line therapy. Interestingly though, TTP 
Table 3. Main phase iii trials of trastuzumab and lapatinib in Her2-positive metastatic breast cancer.
Characteristics Number of patients Regimen Endpoints/outcome References
Trastuzumab
   First-line setting 469
a + C or pac 
+/- Trast
(arm a: +Trast, arm b: -Trast)
TTp:
7.4 vs 4.6 mo
(P<.001)
OS:
25.1 vs 20.3 
mo (P<.046)
33
   Trast-pretreated 482 Cap +/- Trast(arm a: +Trast, arm b: -Trast)
pFS:
8.2 vs 5.6 mo
(P=.03)
43
   er+, postm (TandeM trial) 207 anastr +/- Trast(arm a: +Trast,  arm b: -Trast)
pFS:
4.8 vs 2.4 mo
(P=.0016)
Orr:
20.3 vs 6.8%
(P=.018)
75
Lapatinib
   a, T, Trast pretreated 324 Cap +/- Lap(arm a: +Lap, arm b: -Lap)
TTp:
8.4 vs 4.4 mo
(P<.001)
62
   First-line setting
   (initially unknown Her2 
   status)
579
pac+/- Lap
[arm a (49/291=Her2+): +Lap],    
[arm b (37/288=Her2+): -Lap)],
analysis of Her2+ cases
TTpn:
46.4 vs 25.1 w
(P=.005)
Orr:
63.3 vs 37.8%
(P=.023)
63
    Second-line setting   
   (pretreated on a-T regimen, 
   progressed on Trast)
296 Lap +/- Trast(arm a: +Trast,  arm b: -Trast)
pFS:
12 vs 8.4 w
(P=.029)
Cbr:
24.7 vs 12.4%
(P=.02)
66
   er+ 1,286(Her2+= 219)
Letr +/- Lap
[arm a (111=Her2+): +Lap],    
[arm b (108=Her2+): -Lap)]
pFS:
8.3 vs 3 mo
(P=.019)
Orr:
28 vs 15%
(P=.02)
76
anastr: anastrazole, a: anthracycline, Cap: capecitabine, C: cyclophosphamide, Lap: lapatinib, Letr: letrozole, pac: paclitaxel, T: taxane, Trast: Trastuzumab, er: estrogen receptor, 
postm: postmenopausal, OS: overall survival, Orr: overall response rate, TTp: time to progression, Mo: months, W: weeks, Cbr: clinical benefit ratio
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Table 4. Main trials on novel Her2 therapeutic strategies in Her2-positive metastatic breast cancer. 
Trial/Characteristics Number of patients Arms/Regimen Endpoints/outcomes References
T-DM1
   eMiLia 
   (phase iii trial,
   Trast-T pretreated pts)
978
T-dM1
vs
Cap - Lap
pFS:
9.6 vs 6.4 mo
(Hr: 0.65, 95% 
Ci: 0.55-0.77,
 P<.0001)
OS:
improved for 
T-dM1 arm, 
(median has 
not yet been 
reached)
Obj. rr:
43.6 vs 30.8%
(95% Ci: 
6-19.4, 
P=.0002)
 91
Pertuzumab
   CLeOpaTra 
   (phase iii trial) 808
doc - Trast
+/- per
pFS:
18.5 vs 12.4 mo
(P<.001)
96
   neOSpHere
   (phase iii trial, 
   neo-adjuvant)
417
doc-per
vs doc-Trast
vs doc-Trast-per vs 
Trast-per
pCr:
45.8 vs 29%
(3-drug vs doc-
Trast,
P=.014)
95
Neratinib
   phase ii
   (LabC, MbC) 136
ner 240 mg,
66 pts (prior treated 
with Trast)
70 pts (not treated 
with Trast)
pFS:
40 w
22 w
Cbr:
56%
              24%
97
doc: docetaxel, Lap: Lapatinib, ner: neratinib, per: pertuzumab, LabC: locally advanced breast cancer, MbC: metastatic breast cancer, pCr: pathologic complete response, pFS: progression free survival, OS: 
overall survival, Ob. rr: objective response rate, Mo: months, W: weeks, Cbr: clinical benefit rate
was seven months, being almost the same (8 months) 
for first line, indicating a continuum of activity despite 
progression. OS was 43 months suggesting improved 
survival for those patients. Of course, this was a highly 
selected cohort as patients who progressed rapidly 
after first-line therapy were excluded. Nevertheless, 
these data indicate that eligible patients benefit from 
trastuzumab-based treatment in multiple lines. An im-
portant observation was that 40.2% of the patients in 
the study developed brain metastases and this can be 
easily explained by the inability of trastuzumab to pass 
the blood-brain barrier and the longer survival achieved 
with multiple systemic treatments. Conflicting results 
regarding the utility of continuing trastuzumab beyond 
progression were reported by Montemurro and col-
leagues.45 They retrospectively compared two groups of 
patients, who either received or did not receive trastu-
zumab after progression and found no statistically sig-
nificant difference in their response rate (RR) (28% vs. 
30%), TTP (8.4 vs. 7 months) and median post-pro-
gression survival (20.6 vs. 15.4 months). 
Mechanisms of resistance to trastuzumab
Despite the fact that many patients with HER2-positive 
metastatic breast cancer will benefit from successive 
lines of trastuzumab-containing therapy, they will all 
eventually become resistant. Proposed mechanisms of 
resistance include: 
·  Heterodimerization between HER2 and IGF-1R 
and thus signaling through other growth factors.46 
·  Shedding of the extracellular domain of the recep-
tor leaving the truncated form of the receptor (p95) 
which does not bind to trastuzumab but remains 
active.47
·  Increased expression of the MUC4 membrane gly-
coprotein, which inhibits the interaction of trastu-
zumab with the HER2 receptor.48
·  Activating mutations of AKT and decreased levels 
of phosphatase and tensin homolog (PTEN).49
·  Transcriptional upregulation of HER2 gene ex-
pression.50
·  Down-regulation of p27kip1, a downstream effec-
tor of multiple growth factor receptor pathways.51
·  Expression of low-affinity Fc receptor polymor-
phisms on immune effector cells.52
·  Decreased expression of the cyclin-dependent ki-
nase inhibitor p27.53 
targeting the hER2 receptor—lapatinib
Lapatinib is an orally administered, reversible, selective 
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inhibitor of the intracellular tyrosine kinase domains of 
EGFR/ErbB1 and HER2/ErbB2.54 Lapatinib exerts 
its anti-tumor activity through:
·  Inhibition of tumor growth by means of inhibition 
of activation of downstream signalling for cell pro-
liferation and survival.55 
·  Induction of apoptosis in HER2- and EGFR-
overexpressing cells.56
·  Inhibition of phosphorylation of the truncated form 
of the HER2 receptor (HER2p95).57
There is no cross-resistance between lapatinib and 
trastuzumab, while lapatinib induces apoptosis in trastu-
zumab-resistant cell lines.49 It effectively crosses the 
blood-brain barrier and is active in central nervous sys-
tem (CNS) metastatic disease.58 An additive in vitro ef-
fect was also seen when combined with 5-fluorouracil.59
Lapatinib as first-line treatment
Initially, phase I and II studies evaluated lapatinib as 
a single agent, achieving RR between 1.4% to 7.7%60 
in heavily pretreated patients and 24% when given as 
first line.61 Two phase III trials evaluated lapatinib in 
combination with chemotherapy as second- and first-
line treatment, respectively, and led to the approval of 
lapatinib by the FDA. The first trial62 enrolled patients 
with advanced HER2-positive breast cancer previously 
treated with a taxane, an anthracycline and trastu-
zumab. Patients were treated with either single agent 
capecitabine, 2500mg/m2 daily for 14 days on a 21-day 
cycle or capecitabine 2000 mg/m2 on the same sched-
ule plus lapatinib 1250 mg daily. After the accrual of 
324 patients, an interim analysis showed a significant 
improvement in TTP from 4.4 months to 8.4 months 
in favor of the combination arm [HR: 0.49 (CI 0.34-
0.71) P<.001)] that was the primary study endpoint. 
Accrual was terminated after recommendation from an 
independent data safety monitoring committee. 
The second phase III study,63 tested lapatinib in 
combination with paclitaxel versus paclitaxel and pla-
cebo in the first line setting in patients with HER2 
negative or uncharacterized metastatic breast cancer. 
In a total of 579 evaluable patients, no significant dif-
ferences were observed in TTP, event-free survival and 
OS between the two arms. However, in the subset of 
patients with HER2-positive tumors (49 of 291 in the 
combination arm and 37 of 288 in the monotherapy 
arm) ORR (63.3% vs. 37.8%; P=.023), clinical benefit 
ratio (CBR) (69.4% vs. 40.5%; P=.011) and TTP (46.4 
vs. 25.1 weeks; P=.005) were significantly improved. 
Lapatinib as second-line treatment
Phase II studies that evaluated lapatinib as single agent 
after trastuzumab-based therapy showed minimal ac-
tivity with RR ranging from 1.4% to 5.1%. However, 
in another study in which lapatinib monotherapy64 was 
given in patients with HER2-overexpressing relapsed 
or refractory inflammatory breast cancer, 39% had a 
partial response. Median PFS was 14.6 weeks (95% 
CI 12.1-16.0) with a median duration of response of 
20.9 weeks (12.7-32.1). The likelihood of response to 
lapatinib was not affected by previous treatment with 
trastuzumab. 
Pre-clinical data suggested a synergistic effect 
between trastuzumab and lapatinib in HER2-
overexpressing tumors.65 It seems that lapatinib can 
partially restore sensitivity to trastuzumab in patients 
previously exposed to the drug. This synergistic effect 
can be explained by a lapatinib stabilization and accu-
mulation of inactive HER2 receptors at the cell surface, 
which leads to enhanced trastuzumab-dependent, im-
mune-mediated cytotoxicity. 
A randomized phase III study presented initially at 
ASCO 200866 evaluated women with HER2-positive 
MBC who had received prior anthracycline and tax-
ane therapy and had progressed on trastuzumab. Two 
hundred ninety-six patients were randomized to receive 
either lapatinib (1500 mg daily) or lapatinib (1000 mg 
daily) plus trastuzumab (2 mg/kg weekly after 4 mg/
kg loading dose). If patients progressed on the lapatinib 
arm, they could cross over to the combination arm. 
PFS was 8.4 weeks vs. 12 weeks (P=.029) and CBR 
12.4% vs. 24.7% (P=.02) for the lapatinib-only arm 
vs. the combination arm, respectively. RR and median 
OS were also improved but their differences were not 
statistically significant. Both trastuzumab and lapatinib 
have shown significant activity when combined with 
chemotherapy in the first and second line treatment of 
metastatic HER2-positive breast cancer. Several ques-
tions though still remain unanswered: 
 1.  Which agent should be used first, trastuzumab 
or lapatinib? 
2.  Should lapatinib be used in combination with a 
different chemotherapy drug after progression on 
lapatinib-based chemotherapy in the first line?
 3.  Is the combination of trastuzumab and lapatinib 
plus chemotherapy better than either agent plus 
chemotherapy in the first line?
Currently, a randomized, open-label, phase III study 
of taxane-based chemotherapy with lapatinib or trastu-
zumab first line therapy for women with HER2 posi-
tive metastatic breast cancer is designed to determine 
which is the best anti-HER2-targeted agent to be used 
in combination with chemotherapy in the first-line 
setting.67 Another phase III trial will test whether the 
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addition of lapatinib to trastuzumab in patients who 
either responded or achieved stable disease with trastu-
zumab-based chemotherapy is better than continuing 
trastuzumab alone.68
Lapatinib for the treatment of CNS disease 
CNS metastases are more common in patients with 
HER2-positive tumors.69 Increased frequency of brain 
metastases has been observed in patients treated with 
trastuzumab, which can be as high as 40% due to the 
inability of trastuzumab to cross the blood-brain bar-
rier (BBB).70 Lapatinib on the other hand is a small 
molecule that crosses the BBB and can be effective in 
CNS disease. In the largest clinical trial which exam-
ined the effect of lapatinib monotherapy71 in patients 
with CNS disease, 15 (6%) out of 242 patients had an 
objective response with a mean absolute CNS lesion 
volumetric reduction of 3.2 cm2 (range, 0.7-29.7 cm2). 
Response was defined as a 50% volumetric reduction of 
CNS lesions without development of a new lesion or 
increase in the dose of steroids, progressing neurologic 
symptoms and signs or progressing non-target lesions. 
Patients who progressed on treatment were treated 
with the combination of capecitabine and lapatinib. Ten 
(20%) of 51 patients had more than 50% and another 
18 (35%) patients had more than 20% volumetric re-
duction of CNS metastases making the combination of 
capecitabine and lapatinib the treatment of choice for 
patients with brain metastases even after progression 
on lapatinib monotherapy. Currently, the combination 
of lapatinib with temozolomide72 is being tested in clin-
ical trials. The main trials on trastuzumab and lapatinib 
are summarized in Table 3.
Combining anti-hER2 targeted drugs with hormonal 
treatments
There is a crosstalk between downstream pathways of 
HER2 and/or EGFR and ER.73 Almost half of HER2 
positive breast cancers co-express ERs. There are stud-
ies that provide evidence that the concurrent use of 
trastuzumab and tamoxifen can restore sensitivity to 
tamoxifen in resistant lines. The same has been ob-
served when lapatinib was combined with tamoxifen. 
Both anti-HER2 agents have been combined with aro-
matase inhibitors and it seems that the two drugs act 
synergistically. 
A meta-analysis that included 2379 patients from 
12 studies74 showed a high correlation between HER2 
overexpression and hormonal treatment failure (tamox-
ifen, AIs, megestrol acetate and others) that was even 
higher when the few ER-negative patients were exclud-
ed.
The results from the TAnDEM (Trastuzumab 
and Anastrazole Directed Against Estrogen Receptor-
Positive, HER2-Positive Mammary Carcinoma)75 trial 
have been recently reported. Two hundred and seven 
postmenopausal breast cancer patients with ER and 
HER2 positive tumors were randomly assigned to anas-
trazole plus trastuzumab (103 patients) or anastrazole 
monotherapy (104 patients). The primary endpoint was 
PFS. Median PFS was 4.8 months for the combination 
vs. 2.4 months for the anastrazole monotherapy group 
(HR: 0.63, CI, 0.47 to 0.84, P=.0016). Furthermore, 
median PFS was longer in both arms (5.6 vs. 3.8 months, 
P=.006) in those patients who were found to be ER pos-
itive by central assessment. ORR was also higher for the 
combination vs. the monotherapy group (20.3 vs. 6.8%, 
P=.018) as was the CBR (42.7 vs. 27.9%, P=.026). OS 
was also prolonged (28.5 vs. 23.9 months, P=.325). 
Although not statistically significant, this improvement 
in survival was observed despite the crossover of 73 pa-
tients from the monotherepy to the combination arm at 
disease progression. 
Another randomized phase III trial examined the 
combination of lapatinib and letrozole vs. letrozole and 
placebo. Of 1286 postmenopausal women with ER+ 
metastatic breast cancer who received either lapatinib 
1500 mg with letrozole 2.5mg or letrozole 2.5mg or pla-
cebo, 219 (17%) patients were HER2-positive of which 
111 received the combination and 108 received letrozole 
with placebo.76 The addition of lapatinib to letrozole in 
this patient population significantly decreased the risk of 
disease progression with PFS being 8.3 months for the 
combination vs. 3 months for the letrozole-placebo arm 
(HR=0.71; 95% CI, 0.53 to 0.96; P=.019). ORR was 
28% vs. 15% (odds ratio OR=0.4; 95% CI, 0.2 to 0.9; 
P=.021). CBR was also improved (48% vs. 29%, respec-
tively, OR=0.4; 95% CI, 0.2 to 0.8; P=.003). A statisti-
cally significant increase in the overall survival has not 
been observed with OS being 33.3 months for the com-
bination and 32.5 months for the letrozole-placebo arm 
(HR=0.74; 95% CI, 0.5 to 1.1; P=.114). An interesting 
observation in this study was that in the 952 patients 
with HER2 negative tumors, the researchers identified 
a subgroup (200 patients) who showed a non-signifi-
cant trend toward prolonged PFS (8.3 vs. 3.1 months 
(HR=0.78; 95% CI, 0.57 to 1.07; P=.117). These pa-
tients had experienced relapse less than six months since 
prior tamoxifen discontinuation. A possible explanation 
could be the fact that an enhancement of growth factor 
activity can be seen in association with endocrine resis-
tance, and indeed, 20% of patients with HER2 negative 
tumors can be found HER2 positive if re-biopsied at the 
the time of disease progression/hormone resistance. 
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Evolving novel anti-hER2 strategies
Novel approaches targeting the HER2 pathway are 
now available in the armamentarium. These approaches 
showed efficacy when tested in preclinical models.77-81 
Initially, phase I trials tested their safety and due to 
their tolerable profile further investigation has been 
performed.82-85 We present the most important agents 
such as T-DM1, pertuzumab, neratinib, afatinib and 
ertumaxomab and related phase II and III trials that 
have been conducted. The main trials are summarized 
in Table 4.
Trastuzumab conjugated to an anti-microtubule agent
T-DM1 consist of trastuzumab conjugated to an anti-
microtubule agent (a derivative of maytansine). Also 
known as trastuzumab emmtansine, it is a novel ap-
proach for overcoming resistance to trastuzumab. DM1 
is a potent anti-microtubule agent with in vitro cytotox-
icity more than 1000 times higher than any other che-
motherapeutic agent.86 In a phase II study, 107 patients 
with metastatic trastuzumab refractory disease were 
assessed after T-DM1 administration. Complete re-
sponse was observed in one patient and partial response 
in 41. The objective RR was 25% and the CBR 34.8%.87 
Another phase II trial enrolled 110 patients who 
had previously received a median of seven prior agents. 
An objective RR of 32.7% and a CBR of 44.5% were 
evaluated.88 In addition, another randomized phase II 
trial evaluated T-DM1 vs trastuzumab/docetaxel in 
first-line, HER2-positive MBC. A significant increase 
of PFS was reported with the T-DM1 arm (14.2 vs 9.2 
months). In 137 patients enrolled, the objective RR in 
T-DM1 arm was of 47.8% as compared with 41.4% 
for the other arm.89 Interestingly, a single arm phase II 
study evaluated the combination of T-DM1 and per-
tuzumab in relapsed (n=46) and previously untreated 
patients (n=21). A RR of 57.1% and 34.8% was ob-
served in untreated and relapsed group of patients re-
spectively.90 Patient tolerability was good with fatigue, 
nausea and  thrombocytopenia the most common ad-
verse events. Left ventricular ejection fraction (LVEF) 
decline has been reported but seems to be rare.
Recently, the results of the EMILIA study, a phase 
III trial of T-DM1 compared with capecitabine plus 
lapatinib provided convincing evidence. OS was im-
proved for patients receiving T-DM1. Furthermore, me-
dian OS has not been reached vs 23.3 mo (HR=0.621, 
95% CI: 0.475–0.813, P=.0005). Median PFS was im-
proved also; 9.6 months in the T-DM1 arm compared 
with 6.4 months (HR=0.650, 95% CI: 0.55–0.77, 
P<.0001). The ORR was significantly higher in the 
T-DM1 group at 43.6% vs 30.8% in the (95% CI: 6.0–
19.4, P=.0002). Also greater safety was demonstrated; 
the incidence of adverse events, toxicity was in favor for 
the T-DM1 arm; cardiac toxicity was not increased.91
Pertuzumab
Pertuzumab is a monoclonal antibody that targets 
HER2 extracellular domain at a different epitope 
than trastuzumab. Trastuzumab, although effective 
against HER2 homodimers, is not active against li-
gand-induced HER2 heterodimers. EGFR/HER2 and 
HER2/HER3 heterodimers are important in breast 
cancer proliferation through the HER2 pathway and 
also in bypassing trastuzumab inhibition. Pertuzumab 
inhibits dimerization with other HER receptors and 
downregulates MAPK and PI3K/Akt signaling path-
ways.92 In a single arm, phase II study, the pertuzum-
ab-trastuzumab combination was evaluated in 11 pa-
tients with HER2 positive MBC. The median TTP 
was 6 weeks and the objective RR 18% (no CR was 
observed).93 Six cases with left ventricular dysfunction 
were reported (3 grade I, 2 grade II, 1 grade III), but 
using a lower limit of LVEF cut-off of 55%.
In addition, Baselga and co-investigators evaluated 
the same combination in 66 patients trastuzumab re-
fractory HER2 positive MBC. The median PFS was 
5.5 months with an objective RR of 24.2% (CR: 7.6%, 
PR: 16.7%).94 Contrary to the previous study, cardio-
toxicity was not a major issue with only three patients 
with an asymptomatic LVEF decline >10%. In two pa-
tients LVEF recovery was seen without treatment in-
terruption. Diarrhea, fatigue, nausea and rash were the 
most common toxicities. 
In the NEOSPHERE trial, patients with operable 
locally advanced or inflammatory breast cancer received 
the subsequent regimens in the neoadjuvant setting. 
Of 417 patients were randomized to receive docetaxel-
pertuzumab, docetaxel-trastuzumab, docetaxel-trastu-
zumab-pertuzumab or trastuzumab-pertuzumab, the 
three-drug combination presented the higher patho-
logic complete response rate (45.8% vs 29% of DOC-
TRAST combination, P=.014). Even in the arm that 
received only targeted therapies without chemotherapy 
a pCR rate of 16.8% was observed.95 The recently pre-
sented data of CLEOPATRA trial showed that dual 
HER2 blockade improves PFS. The 808 patients en-
rolled in this phase III trial received docetaxel plus 
trastuzumab combined with pertuzumab or placebo. 
The pertuzumab arm presented significantly prolonged 
PFS (18.5 vs 12.4 months; P<.001). No decrease of 
LVEF was evaluated. In the pertuzumab group the 
rates of febrile neutropenia and diarrhea of grade 3 or 
above were higher than in the control group.96
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Neratinib
Neratinib is an orally administered, low molecular 
weight, irreversible pan-HER receptor tyrosine kinase 
inhibitor. A phase II trial tested the activity of neratinib 
in patients with HER2 positive by FISH in locally ad-
vanced or metastatic breast cancer who either received 
or did not receive trastuzumab therapy in the past.97 
Patients with prior (n=66) on no prior trastuzumab 
treatment (n=70) were recruited and received 240 mg of 
neratinib once daily. Median PFS was 40 and 22 weeks, 
and the CBR was 56% and 24%, respectively. Based on 
these results, phase III studies with neratinib are being 
conducted in women with HER2-positive breast cancer. 
Afatinib
Afatinib is an oral, small molecule irreversible HER fam-
ily TKI. In a single arm, phase II study, 41 patients with 
HER2 positive, trastuzumab refractory MBC were en-
rolled. PR was evaluated in 4 patients and stable disease 
in 8. Diarrhea (22%) and rash (9.8%) were the most com-
mon adverse events.98 
Ertumaxomab
Ertumaxomab is a trifunctional, bispecific monoclonal 
antibody that targets both HER2 receptor, CD3 antigen 
on T cells and activates fcgamma receptors. The complex 
induces the activation of T cells, dendritic cells, natu-
ral killers and macrophages that through phagocytosis 
provoke tumor death.99 In a phase I trial a response was 
evaluated in 15 patients with MBC. The most common 
adverse events were nausea, vomiting, fever, lymphocyto-
penia and elevated liver enzymes.100 The results of further 
phase II studies are eagerly awaited.
Conclusions
Over the past decade, we have witnessed a shift in the 
treatment of breast cancer, from chemotherapy to com-
binations of chemotherapy and targeted therapies. 
Increased knowledge of the molecular biology of breast 
cancer has enabled us to be more specific in the treat-
ment of the different types of breast cancer. Drugs are 
now designed to target molecules that are important for 
the survival of cancer cells. The ER and HER2 receptors 
have emerged as the most important targets and determi-
nants of individualized treatment. In the following years 
we expect to see an increasing number of targeted agents, 
promising prolonged survival and better quality of life for 
cancer patients. 
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